Last reviewed · How we verify
Thalomid
At a glance
| Generic name | Thalomid |
|---|---|
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago |
| Target | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Protein cereblon |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Crow-Fukase (POEMS) syndrome
- Erythema nodosum leprosum
- Multiple myeloma
Common side effects
- Hypocalcemia
- Fatigue
- Constipation
- Neuropathy-sensory
- Edema
- Dyspnea
- Muscle weakness
- Leukocytes (decreased)
- Rash/desquamation
- Anorexia
- Nausea
- Confusion
Serious adverse events
- Thrombosis/embolism
- Dyspnea
- Fatigue
- Neutrophils (decreased)
- Neuropathy-motor
- Constipation
- Confusion
- Muscle weakness
- Leukocytes (decreased)
- Edema
Key clinical trials
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (PHASE2)
- Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome (NA)
- Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis (PHASE3)
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis (PHASE2)
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors (PHASE2)
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (PHASE4)
- EDOCH Alternating With DHAP for New Diagnosed Younger MCL (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |